Adipokine Resistin Levels at Time of Pediatric Crohn Disease Diagnosis Predict Escalation to Biologic Therapy.
Crohn disease
adipokines
resistin
visceral adipose tissue
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
20
04
2020
pubmed:
27
9
2020
medline:
9
2
2022
entrez:
26
9
2020
Statut:
ppublish
Résumé
Hypertrophy of visceral adipose tissue (VAT) is a hallmark of Crohn disease (CD). The VAT produces a wide range of adipokines, biologically active factors that contribute to metabolic disorders in addition to CD pathogenesis. The study aim was to concomitantly evaluate serum adipokine profiles and VAT volumes as predictors of disease outcomes and treatment course in newly diagnosed pediatric patients with CD. Pediatric patients ages 6 to 20 years were enrolled, and their clinical data and anthropometric measurements were obtained. Adipokine levels were measured at 0, 6, and 12 months after CD diagnosis and baseline in control patients (CP). The VAT volumes were measured by magnetic resonance imaging or computed tomography imaging within 3 months of diagnosis. One hundred four patients undergoing colonoscopy were prospectively enrolled: 36 diagnosed with CD and 68 CP. The serum adipokine resistin and plasminogen activator inhibitor (PAI)-1 levels were significantly higher in patients with CD at diagnosis than in CP. The VAT volume was similar between CD and CP. Baseline resistin levels at the time of diagnosis in patients with CD who were escalated to biologics was significantly higher than in those not treated using biologic therapy by 12 months (29.8 ng/mL vs 13.8 ng/mL; P = 0.004). A resistin level of ≥29.8 ng/mL at the time of diagnosis predicted escalation to biologic therapy in the first year after diagnosis with a specificity of 95% (sensitivity = 53%; area under the curve = 0.82; P = 0.015 for model with log-scale). There was a significantly greater reduction in resistin (P = 0.002) and PAI-1 (P = 0.010) at the 12-month follow-up in patients on biologics compared with patients who were not treated using biologics. Serum resistin levels at diagnosis of pediatric CD predict the escalation to biologic therapy at 12 months, independent of VAT volumes. Resistin and PAI-1 levels significantly improved in patients with CD after treatment using biologics compared with those not on biologics. These results suggest the utility of resistin as a predictive biomarker in pediatric CD.
Sections du résumé
BACKGROUND
Hypertrophy of visceral adipose tissue (VAT) is a hallmark of Crohn disease (CD). The VAT produces a wide range of adipokines, biologically active factors that contribute to metabolic disorders in addition to CD pathogenesis. The study aim was to concomitantly evaluate serum adipokine profiles and VAT volumes as predictors of disease outcomes and treatment course in newly diagnosed pediatric patients with CD.
METHODS
Pediatric patients ages 6 to 20 years were enrolled, and their clinical data and anthropometric measurements were obtained. Adipokine levels were measured at 0, 6, and 12 months after CD diagnosis and baseline in control patients (CP). The VAT volumes were measured by magnetic resonance imaging or computed tomography imaging within 3 months of diagnosis.
RESULTS
One hundred four patients undergoing colonoscopy were prospectively enrolled: 36 diagnosed with CD and 68 CP. The serum adipokine resistin and plasminogen activator inhibitor (PAI)-1 levels were significantly higher in patients with CD at diagnosis than in CP. The VAT volume was similar between CD and CP. Baseline resistin levels at the time of diagnosis in patients with CD who were escalated to biologics was significantly higher than in those not treated using biologic therapy by 12 months (29.8 ng/mL vs 13.8 ng/mL; P = 0.004). A resistin level of ≥29.8 ng/mL at the time of diagnosis predicted escalation to biologic therapy in the first year after diagnosis with a specificity of 95% (sensitivity = 53%; area under the curve = 0.82; P = 0.015 for model with log-scale). There was a significantly greater reduction in resistin (P = 0.002) and PAI-1 (P = 0.010) at the 12-month follow-up in patients on biologics compared with patients who were not treated using biologics.
CONCLUSIONS
Serum resistin levels at diagnosis of pediatric CD predict the escalation to biologic therapy at 12 months, independent of VAT volumes. Resistin and PAI-1 levels significantly improved in patients with CD after treatment using biologics compared with those not on biologics. These results suggest the utility of resistin as a predictive biomarker in pediatric CD.
Identifiants
pubmed: 32978938
pii: 5911945
doi: 10.1093/ibd/izaa250
pmc: PMC8355503
doi:
Substances chimiques
Adipokines
0
Plasminogen Activator Inhibitor 1
0
Resistin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1088-1095Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK097948
Pays : United States
Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):915-919
pubmed: 29287006
Am J Hum Genet. 2005 Jul;77(1):64-77
pubmed: 15897982
J Immunol. 2005 May 1;174(9):5789-95
pubmed: 15843582
Clin Microbiol Infect. 2013 Apr;19(4):314-20
pubmed: 23506525
Inflamm Bowel Dis. 2011 Jun;17(6):1314-21
pubmed: 21560194
J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74
pubmed: 17460505
Clin Gastroenterol Hepatol. 2011 Aug;9(8):684-687.e1
pubmed: 21642015
Int J Obes (Lond). 2007 Dec;31(12):1806-17
pubmed: 17593903
J Crohns Colitis. 2018 Nov 09;12(10):1139-1150
pubmed: 29309546
J Pediatr Gastroenterol Nutr. 2017 Dec;65(6):633-638
pubmed: 28362691
Gastroenterology. 2019 Feb;156(3):614-622
pubmed: 30342031
Eur J Gastroenterol Hepatol. 2008 Sep;20(9):912-6
pubmed: 18794606
AJR Am J Roentgenol. 2011 Aug;197(2):482-7
pubmed: 21785098
Br J Surg. 1992 Sep;79(9):955-8
pubmed: 1422768
Ann Gastroenterol. 2016 Oct-Dec;29(4):424-438
pubmed: 27708507
Inflamm Bowel Dis. 2014 Dec;20(12):2286-91
pubmed: 25222655
Inflamm Bowel Dis. 2011 Jan;17(1):112-7
pubmed: 20812330
Inflamm Bowel Dis. 2006 Feb;12(2):100-5
pubmed: 16432373
Adv Data. 2000 Jun 8;(314):1-27
pubmed: 11183293
Inflamm Bowel Dis. 2002 Jul;8(4):244-50
pubmed: 12131607
BMJ. 2017 Sep 20;358:j3951
pubmed: 28931512
Inflamm Bowel Dis. 2015 Nov;21(11):2590-7
pubmed: 26222339
Cardiovasc Res. 2017 Jul 1;113(9):1009-1023
pubmed: 28838042
Lancet. 2017 Apr 29;389(10080):1710-1718
pubmed: 28259484
Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1070-4
pubmed: 17998831
Gastroenterology. 2015 Nov;149(6):1415-24
pubmed: 26193622
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
Aliment Pharmacol Ther. 2007 Feb 15;25(4):429-40
pubmed: 17269998
Gut. 2012 Jan;61(1):86-94
pubmed: 21930728
Am J Gastroenterol. 2018 May;113(5):694-701
pubmed: 29535417
Dig Dis Sci. 2010 Mar;55(3):733-8
pubmed: 19267197
N Engl J Med. 2012 Oct 18;367(16):1519-28
pubmed: 23075178
Inflamm Bowel Dis. 2019 Feb 21;25(3):592-600
pubmed: 30215805
J Pediatr. 2013 Jul;163(1):17-22
pubmed: 23522861
Sci Transl Med. 2019 Mar 6;11(482):
pubmed: 30842312
Eur J Gastroenterol Hepatol. 2007 Sep;19(9):789-94
pubmed: 17700265
J Pediatr Gastroenterol Nutr. 2012 Jul;55(1):93-108
pubmed: 22516861
J Clin Invest. 2017 Jan 3;127(1):74-82
pubmed: 28045400
PLoS One. 2015 Jul 15;10(7):e0132891
pubmed: 26176769